Mr. Ramzi Benamar reports
BELLUS HEALTH TO PRESENT ON THE PATIENT EXPERIENCE AND THE BURDEN OF REFRACTORY CHRONIC COUGH AT THE AMERICAN ACADEMY OF ALLERGY, ASTHMA & IMMUNOLOGY ANNUAL MEETING
Two abstracts describing the patient medical journey and the negative impact of RCC on quality of life will be presented by Bellus Health Inc. at the upcoming American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, being held in San Antonio, Tex., from Feb. 24 to Feb. 27, 2023.
Poster presentation details
Burden of Cough in Refractory Chronic Cough Populations Enrolled in A Phase 2b Study of the P2X3 Antagonist BLU-5937
Sunday, Feb. 26, 10:45 a.m. to 11:45 a.m. ET/9:45 to 10:45 a.m. CT
Title: Cough-Associated Diagnostic Journey of Participants in a Phase 2b Study in Refractory Chronic Cough
Date/time: Sunday, Feb. 26, 10:45 a.m. to 11:45 a.m. ET/9:45 to 10:45 a.m. CT
The posters are currently available on the congress platform. Following the conference, the presentation materials will be available in the "scientific publications" section of Bellus Health's website.
Additionally, conference attendees are invited to visit Bellus's booth (No. 2064) during exhibit hours to learn more about the company's CALM phase 3 program in RCC.
About Bellus Health Inc.
Bellus Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other hypersensitivity indications. The company has successfully completed a phase 2b trial in RCC and has initiated the CALM phase 3 clinical program (CALM-1 and CALM-2).
Chronic cough is a cough lasting longer than eight weeks. When the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately nine million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social and psychological effects on health and quality of life. Currently, there is no specific therapy approved for RCC outside of Japan and Switzerland and treatment options are limited.
We seek Safe Harbor.
© 2023 Canjex Publishing Ltd. All rights reserved.